Skip to main content
. Author manuscript; available in PMC: 2019 Jul 1.
Published in final edited form as: PET Clin. 2018 Jul;13(3):437–444. doi: 10.1016/j.cpet.2018.02.009

Figure 3.

Figure 3

Scatterplot demonstrating a strong correlation between 18F-fluciclovine SUV and percent tumor volume reduction on pathology in 24 patients with breast cancer following neoadjuvant therapy. Note that a 100% reduction in SUV on PET correlated with a 90-100% reduction in tumor reduction. Thus, while the correlation was strong, a 100% reduction in 18F-fluciclovine SUV could not distinguish a pathologic complete response from a pathologic non-complete response. ρ = Spearman’s rho.

Adapted from Ulaner GA, Goldman DA, Corben A, et al. Prospective clinical trial of 18F-fluciclovine PET/CT for determining the response to neoadjuvant therapy in invasive ductal and invasive lobular breast cancers. J Nucl Med. 2017;58(7):1037-1042; with permission.